Wolfe Research Assumes argenx SE (ARGX) at Outperform
- Wall St slumps as investors fret on rate hikes and recession
- Think September Was Bad? Watch Out for 'Octoberphobia', Stock Trader's Almanac Warns
- Goldman Sachs Slashes Year-End Target on S&P 500 to 3,600
- Oil: The 'R'-Word Rules as U.S. Crude Below $80 for Worst Week in 7
- Bond Crash of 2022 is a 'Doozy' - BofA
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Wolfe Research analyst Andrew Galler assumes coverage on argenx SE (NASDAQ: ARGX) with a Outperform rating.
The analyst comments "In this deck, we discuss key investor debates such as efgartigimod's position in the FcRn pecking order, the approvability and launch expectations for efgartigimod in gMG, and expectations for ITP and PV."
Shares of argenx SE closed at $309.40 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AppLovin (APP) the Best Category Leader in Mobile Ad Network Space - Morgan Stanley
- argenx Submits Biologics License Application to U.S. Food and Drug Administration for Subcutaneous Efgartigimod for Treatment of Generalized Myasthenia Gravis
- Roth Capital Downgrades Tritium (DCFC) to Neutral
Create E-mail Alert Related CategoriesAnalyst Comments, New Coverage
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!